New Anti-VEGF Drugs in Ophthalmology

被引：16
作者：
Campa, Claudio [1 ]
机构：
[1] St Anna Univ Hosp, Eye Clin, Ferrara, Italy
来源：
CURRENT DRUG TARGETS | 2020年 / 21卷 / 12期
关键词：
Anti-VEGF; conbercept; brolucizumab; port delivery system; ranibizumab; abicipar pegol; faricimab; ENDOTHELIAL GROWTH-FACTOR; DOMAIN-CONTAINING RECEPTOR; DIABETIC MACULAR EDEMA; ANKYRIN REPEAT PROTEIN; BEVACIZUMAB AVASTIN(R); INTRAVITREAL INJECTION; LEGAL BLINDNESS; ABICIPAR PEGOL; FUSION PROTEIN; EFFICACY;
D O I：
10.2174/1389450121666200428101738
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
引用
收藏
页码：1194 / 1200
页数：7
相关论文
共 41 条
[1]   Innovative therapies for neovascular age-related macular degeneration [J].
Al-Khersan, Hasenin ;
Hussain, Rehan M. ;
Ciulla, Thomas A. ;
Dugel, Pravin U. .
EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (15) :1879-1891
[2]  
[Anonymous], 2015, INVEST OPHTH VIS SCI
[3]   Pharmacokinetics of intravitreal bevackumab (avastin) [J].
Bakri, Sophie J. ;
Snyder, Melissa R. ;
Reid, Joel M. ;
Pulido, Jose S. ;
Singh, Ravinder J. .
OPHTHALMOLOGY, 2007, 114 (05) :855-859
[4]   Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010 [J].
Bloch, Sara Brandi ;
Larsen, Michael ;
Munch, Inger Christine .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2012, 153 (02) :209-213
[5]  
Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
[6]   The efficacy and safety of aflibercept and conbercept in diabetic macular edema [J].
Cai, Siwei ;
Yang, Qianhui ;
Li, Xiaorong ;
Zhang, Yan .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 :3471-3483
[7]   Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration [J].
Callanan, David ;
Kunimoto, Derek ;
Maturi, Raj K. ;
Patel, Sunil S. ;
Staurenghi, Giovanni ;
Wolf, Sebastian ;
Cheetham, Janet K. ;
Hohman, Thomas C. ;
Kim, Kimmie ;
Lopez, Francisco J. ;
Schneider, Susan .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 34 (10) :700-709
[8]   The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Results from the Randomized Phase 2 Ladder Clinical Trial [J].
Campochiaro, Peter A. ;
Marcus, Dennis M. ;
Awh, Carl C. ;
Regillo, Carl ;
Adamis, Anthony P. ;
Bantseev, Vladimir ;
Chiang, Yawen ;
Ehrlich, Jason S. ;
Erickson, Signe ;
Hanley, William D. ;
Horvath, Joshua ;
Maass, Katie F. ;
Singh, Natasha ;
Tang, Fan ;
Barteselli, Giulio .
OPHTHALMOLOGY, 2019, 126 (08) :1141-1154
[9]   Treatment of Diabetic Macular Edema With a Designed Ankyrin Repeat Protein That Binds Vascular Endothelial Growth Factor: A Phase I/II Study [J].
Campochiaro, Peter A. ;
Channa, Roomasa ;
Berger, Brian B. ;
Heier, Jeffrey S. ;
Brown, David M. ;
Fiedler, Ulrike ;
Hepp, Julia ;
Stumpp, Michael T. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 155 (04) :697-704
[10]  
Chaney P., 2019, PAN90806
12345